Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Short-term Investments (2016 - 2025)

IGC Pharma (IGC) has disclosed Short-term Investments for 10 consecutive years, with $25000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Short-term Investments changed N/A to $25000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $25000.0, a N/A change, with the full-year FY2023 number at $154000.0, changed N/A from a year prior.
  • Short-term Investments was $25000.0 for Q3 2025 at IGC Pharma, down from $98000.0 in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $227000.0 in Q2 2023 to a low of $25000.0 in Q3 2025.
  • A 3-year average of $130833.3 and a median of $126000.0 in 2023 define the central range for Short-term Investments.
  • Biggest YoY gain for Short-term Investments was 49.22% in 2023; the steepest drop was 49.22% in 2023.
  • IGC Pharma's Short-term Investments stood at $88000.0 in 2022, then increased by 11.36% to $98000.0 in 2023, then crashed by 74.49% to $25000.0 in 2025.
  • Per Business Quant, the three most recent readings for IGC's Short-term Investments are $25000.0 (Q3 2025), $98000.0 (Q3 2023), and $227000.0 (Q2 2023).